Abbisko Cayman Limited (HKG:2256)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
13.57
-0.75 (-5.24%)
Dec 15, 2025, 1:44 PM HKT
195.00%
Market Cap9.63B
Revenue (ttm)678.11M
Net Income (ttm)164.35M
Shares Out672.36M
EPS (ttm)0.24
PE Ratio58.68
Forward PE726.19
Dividendn/a
Ex-Dividend Daten/a
Volume653,000
Average Volume2,224,934
Open13.93
Previous Close14.32
Day's Range13.39 - 13.94
52-Week Range4.20 - 19.78
Beta1.48
RSI49.61
Earnings DateMar 3, 2026

About Abbisko Cayman

Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 281
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2256
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.